India launches global cancer care network, 11 nations want to join

India has launched one that will allow the integration of hospitals and cancer care institutes from partner countries with the National Cancer Grid (NCG) in the country. The goal of the network is to eliminate the disparity in cancer care worldwide.

KN Vyas, secretary of the Department of Atomic Energy (DAE) and president of the Atomic Energy Commission, after launching the global cancer care network in Vienna on Tuesday on the sidelines of the 63rd IAEA General Conference, said: I am happy to announce that India is launching NCG-Vishwam Cancer Care Connect (NCG-Vishwam 3C). Vishwam is a Sanskrit word that means universal or global. Through this connection, we will join hands with all partner countries interested in our fight against cancer.

Vyas said: Our partner countries will benefit in different ways through NCG Vishwam connect, such as NCG guidelines for the management of common cancers, second opinion service for patients and doctors, treatment decisions and course availability. Massive open online.

Eleven countries showed interest in the NCG-Vishwam shortly after its launch. I am happy that different hospitals in Russia, Kazakhstan, Vietnam, Nepal, United Arab Emirates, Afghanistan, Jamaica , Bangladesh, Myanmar and Zambia have agreed to be part of the NCG-Vishwam, ”said the DAE secretary. The hospitals in Sri Lanka and Bangladesh conveyed their gratitude through a video message about the worldwide launch of NCG.

“Radioisotopes for cancer detection and treatment are produced exclusively by the department (DAE). The department is also involved in the development of new radiopharmaceuticals and a cobalt teletherapy machine, called Bhabhatron, for cancer treatment, ”he said.

National Cancer Grid is managed by the Tata Memorial Center and was established in 2012 with the vision of creating uniform standards of cancer care across the country. Tata Memorial Center, which is an integral part of DAE, has been a premier cancer care center since 1941 and has achieved an excellent balance with the trilogy of patient care, education and research. The center today has seven hospitals, including the famous Tata Memorial Hospital in Mumbai, and a research institute that addresses the needs of more than five lakh patients each year, including a new lakh patients.

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more